

UNIVERSITY OF COLORADO SCHOOL OF MEDICINE

JOSEPH P. SCHACHT, PH.D.

CURRICULUM VITAE

1. Personal history or biographical sketch

- *Current Position:* Professor and Co-Director
Division of Addiction Science, Prevention, and Treatment
Department of Psychiatry
University of Colorado Anschutz School of Medicine
1890 N. Revere Court, P12-5161
Mail Stop F570
Aurora, CO 80045
Phone: (303) 724-3773
Email: joseph.schacht@cuanschutz.edu

2. Education

- *Undergraduate*
University of Michigan, Ann Arbor, MI
A.B. with Highest Distinction (top 3% of class), with Honors in Psychology, 2004
Majors: Psychology and Philosophy; Minor: Germanic Studies
- *Graduate*
University of Colorado, Boulder, CO
M.A., Psychology, 2006
Ph.D., Clinical Psychology (American Psychological Association-accredited), 2010
Ph.D., Neuroscience, 2010
- *Internship*
Charleston Consortium Psychology Internship Program, Charleston, SC, 2009-2010
(American Psychological Association-accredited)
- *Postdoctoral*
Medical University of South Carolina, Charleston, SC, 2010-2013
NIAAA T32 postdoctoral fellowship

3. Academic appointments

Medical University of South Carolina, Department of Psychiatry & Behavioral Sciences

- **Predoctoral Intern, 2009-2010**
- **Postdoctoral Fellow, 2010-2013**
- **Research Associate, 2013-2015**
- **Assistant Professor, 2015-2019**
- **Associate Professor, 2019**

- **Adjunct Associate Professor**, 2019-2024

College of Charleston, Department of Psychology

- **Adjunct Faculty**, 2011-2012

University of Colorado Anschutz School of Medicine, Department of Psychiatry

- **Associate Professor**, 2019-2026
- **Co-Director**, Division of Addiction Science, Prevention, and Treatment, 2024-present
- **Professor**, 2026-present

4. Hospital, government or other professional positions

- N/A

5. Honors, special recognitions and awards

- 2004: **Phi Beta Kappa**, University of Michigan
- 2004-2005: **University Fellowship**, University of Colorado, Boulder
- 2006-2009: **Ruth L. Kirchstein National Research Service Award**, National Institute on Drug Abuse
- 2010: **Student Merit Travel Award**, Research Society on Alcoholism
- 2010: **Enoch Gordis Research Award Finalist (Pre-doctoral)**, Research Society on Alcoholism
- 2010: **Scientist-Practitioner Award**, Charleston Consortium Psychology Internship Program
- 2011: **Summer Fellowship**, UCLA Advanced Neuroimaging Training Program
- 2012: **Young Investigator Travel Award**, International Behavioural and Neural Genetics Society
- 2012: **Memorial Award**, Research Society on Alcoholism
- 2011-2014: **Junior Investigator Travel Award**, Research Society on Alcoholism
- 2014: **Enoch Gordis Research Award Finalist (Post-doctoral)**, Research Society on Alcoholism
- 2014-2016: **Junior/Senior Scholar**, Alcohol Medical Scholars Program (Director: Marc A. Schuckit, M.D.)
*Competitive 2-year career development program designed to increase participants' skills in delivering education about alcohol and substance use disorders in medical schools
- 2016: **Travel Award**, International Society for Biomedical Research on Alcoholism (ISBRA)
- 2018: **Travel Award**, American College of Neuropsychopharmacology
- 2022: **Associate Member (elected)**, American College of Neuropsychopharmacology

6. Membership in professional organizations

- **Member**, Research Society on Alcohol, 2009-present
 - **Member**, Program Committee, 2016-2017
 - **Member**, Education Committee, 2018-2024
 - **Chair**, Grant Skills Sub-Committee, 2022-2024
 - **Member**, Program Committee, 2019-2021
- **Member**, American Psychological Association, Division 28 (Psychopharmacology and Substance Abuse), 2014-2016

- *Member*, Planning Committee, 2015 Collaborative Perspectives on Addiction (APA, Divisions 28/50) meeting
- **Member**, International Society for Biomedical Research on Alcoholism, 2016-present
- **Associate Member**, American College of Neuropsychopharmacology, 2022-present

7. Major Committee and Service Responsibilities

Colorado School of Public Health

- 2021-present: **Member**, *Scientific Review Council*, Cannabis Research and Policy Project (<https://coloradosph.cuanschutz.edu/research-and-practice/practice/cannabis-research/scientific-review-council>)

Departmental

Medical University of South Carolina

- 2011-2017: **Coordinator**, *Addiction Study Group*, Center for Biomedical Imaging.
- 2014: **Chair**, *Clinical Research Session*, Frontiers in Neuroscience Research Meeting, Neuroscience Institute.
- 2014: **Panelist**, *Preparing a Compelling K99/R00 Application*, College of Graduate Studies.
- 2014-2019: **Member**, *Grand Rounds Committee*, Department of Psychiatry & Behavioral Sciences.
- 2016-2017: **Member**, *Biostatistician Search Committee*, Charleston Alcohol Research Center.
- 2017-2018: **Co-organizer**, *Alcohol Research Breakfast Seminar Series*, Charleston Alcohol Research Center.

University of Colorado Anschutz School of Medicine

- 2020-present: **Member**, *Research Advisory Committee*, Department of Psychiatry.
- 2022-present: **Member**, *Advisory Committee*, University of Colorado Brain Imaging Center.
- 2023-present: **Member**, *Brain and Behavior Innovation Center*, Department of Psychiatry.
- 2023-2024: **Member**, *Incentive Committee*, Department of Psychiatry.
- 2024-2025: **Co-Chair**, *Addiction Psychiatry Medical Director Search Committee*, Center for Dependency, Addiction, and Rehabilitation (CeDAR), Department of Psychiatry.
- 2025: **Member**, *Vice-Chair for Psychology Search Committee*, Department of Psychiatry.

- 2025: **Panelist**, *Research Career Perspectives/Pathways Discussion Panel*, Developmental Psychobiology Research Group, Department of Psychiatry.

Data Safety Monitoring Board (DSMB) Membership:

- 2018-2019: **Study**: “Imaging framework for testing GABAergic/ glutamatergic drugs in bipolar alcoholics”. **PI**: James J. Prisciandaro, Ph.D.
- 2018-2019: **Study**: “Gabapentin for bipolar and cannabis use disorders: Relation to brain glutamate”. **PI**: James J. Prisciandaro, Ph.D.
- 2018-2019: **Study**: “A proof-of-concept trial of *N*-acetylcysteine for adolescent Alcohol Use Disorder”. **PIs**: Kevin C. Gray, M.D., & Lindsay M. Squeglia, Ph.D.
- 2024-present: **Study**: “Testing an Accelerated TMS Protocol for Methamphetamine Use Disorder”. **PI**: Joseph T. Sakai, M.D.

8. Licensure and board certification

- 2013-2019, Psychologist, #1273, South Carolina (inactive)
- 2019-present, Psychologist, #PSY.0005078, Colorado

9. Inventions, intellectual property and patents held or pending

- Anton, R. F., & **Schacht, J. P.** (2026). *Epigenetic moderators of naltrexone efficacy in reducing heavy drinking in individuals diagnosed with alcohol use disorder*. U.S. Patent No. 17/824,784. U.S. Patent and Trademark Office.

10. Review and referee work

- National Institutes of Health Study Section Membership
2021-2025 **Standing Member**, Clinical, Treatment, and Health Services Research Review Subcommittee (AA-3), NIAAA
 - **Co-chair**, October 2024, February 2025 meetings
 - Invited to be chair for 2025-2027, but study section was dissolved as part of NIH peer review consolidation
- National Institutes of Health Study Sections

2019, May	ZAA1 CC (10) (Special Emphasis Panel), NIAAA
2019, October	NAL Study Section (Ad-hoc member), NIH CSR
2020, March	ZAA1 GG (03) M (Special Emphasis Panel), NIAAA
2020, June	NPAS Study Section (Ad-hoc member), NIH CSR
2021, March	ZAA1 GG (03) M (Special Emphasis Panel), NIAAA
2021, March	ZRG1 IFCN-C (02) (Special Emphasis Panel), NIH CSR
2021, June	ZAA1 CC (04) M (Special Emphasis Panel), NIAAA
2026, June	PSUD Study Section (Ad-hoc member, Alternate chair), NIH CSR
- Other Grant Review Activity:

2018, June	Fonds de la Recherche Scientifique (Fund for Scientific Research)-FNRS, Brussels, Belgium
2019, June	Center for Medicinal Cannabis Research, University of California, San Diego
2019, June	Fonds de la Recherche Scientifique (Fund for Scientific Research)-FNRS, Brussels, Belgium

2021, February	Hetzler Foundation for Addiction Research
2021, September	Fonds de la Recherche Scientifique (Fund for Scientific Research)- FNRS, Belgium
2023, April	Fonds de la Recherche Scientifique (Fund for Scientific Research)- FNRS, Belgium
2024, April	AB Nexus Program, University of Colorado Anschutz
2024, July	Czech Science Foundation, Czech Republic
2024, July	Rocky Mountain Cannabis Research Center Pilot Grants, University of Colorado Anschutz
2025, July	Rocky Mountain Cannabis Research Center Pilot Grants, University of Colorado Anschutz
2026, March	Colorado Clinical and Translational Sciences Institute Pre-F Program, University of Colorado Anschutz
2026, April	Mental Health Innovation and Novel Discoveries (MIND) Fund, CU Innovations/Brain and Behavior Innovation Center
2026, July	Rocky Mountain Cannabis Research Center Pilot Grants, University of Colorado Anschutz
2026, August	Fondazione Regionale per la Ricerca Biomedica (Regional Foundation for Biomedical Research), Italy

- Ad hoc journal reviews:
 - Addiction
 - Addiction Biology
 - Alcohol and Alcoholism
 - Alcohol: Clinical & Experimental Research (Outstanding Reviewer, 2021, 2022, 2025)
 - Alcohol Research: Current Reviews
 - American Journal of Drug and Alcohol Abuse
 - American Journal of Psychiatry
 - Behaviour Research and Therapy
 - Biological Psychiatry
 - Biological Psychiatry: Cognitive Neuroscience and Neuroimaging (Top 10 Reviewer, 2018)
 - Brain Structure and Function
 - Current Addiction Reports
 - Drug and Alcohol Dependence
 - Experimental and Clinical Psychopharmacology
 - European Journal of Neuroscience
 - Frontiers in Human Neuroscience
 - Human Brain Mapping
 - International Journal of Neuropsychopharmacology
 - JAMA Psychiatry/Archives of General Psychiatry
 - Journal of Addiction Medicine
 - Journal of Neuroscience Methods
 - Journal of Studies on Alcohol and Drugs
 - Molecular Psychiatry
 - NeuroImage
 - Neuropharmacology
 - Neuropsychopharmacology
 - Psychiatry Research
 - Psychiatry Research: Neuroimaging

- Psychology of Addictive Behaviors
- Psychopharmacology
- Translational Psychiatry

11. Invited extramural lectures and presentations

International

- *Neuroscience-informed treatment of alcohol use disorders: Perspectives for the next generation of addiction scientists.* (2017, February). Heidelberg University/Central Institute of Mental Health/German Society on Addiction Research & Addiction Therapy symposium in honor of the re-allocation of the Chair in Addiction Research, Heidelberg, Germany.
- *Rationale for a randomized controlled trial of oral semaglutide for Alcohol Use Disorder.* (2025, September). Steno Diabetes Center, Copenhagen, Denmark.
- *Rationale for a randomized controlled trial of oral semaglutide for Alcohol Use Disorder.* (2025, September). University of Copenhagen, Copenhagen, Denmark.
- *GABA-B positive allosteric modulation for Alcohol Use Disorder: Clinical update and results of a randomized trial.* (2026, May). 2026 GABA-B Receptor Conference, Cagliari, Italy.

National

- *Using imaging genetics to understand addiction.* (2013, January). Center for Alcohol and Addiction Studies, Brown University, Providence, RI.
- *Alcohol craving in the brain: Neuroimaging and pharmacological manipulation.* (2013, November). National Institute on Drug Abuse Intramural Research Program, Baltimore, MD.
- *Using imaging genetics to understand the development and treatment of addiction.* (2013, November). Department of Psychology, Michigan State University, East Lansing, MI.
- *Alcohol craving in the brain: Neuroimaging and pharmacological manipulation.* (2014, April). Department of Psychology, University of California, Los Angeles, CA.
- *Identification of neural targets for pharmacological treatment in alcohol use disorders.* (2014, September). Treatment Research Center, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
- *Identification of neural targets for pharmacological treatment in alcohol use disorders.* (2014, October). Neuroscience Program, SRI International, Menlo Park, CA.
- *Neuroscience-informed treatment of alcohol use disorders.* (2017, August). Integrative Biosciences Center, Wayne State University, Detroit, MI.
- *Modulation of dopaminergic neurotransmission affects drinking in genetically targeted subgroups.* (2021, March). San Diego State University/University of California, San Diego NIAAA T32 Addictions Seminar, San Diego, CA.
- *Effects of pharmacological and genetic regulation of COMT signaling in Alcohol Use Disorder: A randomized, placebo-controlled trial of tolcapone.* (2022, February). Center for Alcohol and Addiction Studies Rounds Series, Brown University, Providence, RI.

- *How to build and lead a productive alcohol research program.* (2023, April). Center for Alcohol and Addiction Studies, Brown University, Providence, RI.
- *Considering cue-elicited brain activation as an outcome measure in alcohol medications development human laboratory studies.* (2024, September). University of California Washington Center, Washington, DC.
- *Exploring GLP-1 Receptor Agonists as Candidate Medications for Alcohol Use Disorder.* (2024, September). Boulder Peptide Symposium, Boulder, CO.
- *GLP-1 Receptor Agonists for the Treatment of Substance Use Disorders (Discussant).* (2024, October). NIDA-NIAAA Mini-Convention: Frontiers in Addiction Research, Chicago, IL.
- *Neuroimaging in Alcohol Clinical Trials.* (2024, November). Alcohol Clinical Trials Initiative (ACTIVE). (Virtual presentation).
- *A Clinical Laboratory Alcohol Self-Administration Paradigm for Assessing the Effects of Medications for Alcohol Use Disorder.* (2025, March). Alcohol Clinical Trials Initiative (ACTIVE), Rockville, MD.
- *Beyond Obesity and Diabetes: Exploring the Expanded Therapeutic Potential of GLP-1s.* (2025, September). 5th Annual Pharma Life Sciences Virtual Summit. (Virtual presentation).
- *Oral Semaglutide for Alcohol Use Disorder: A Randomized Trial.* (2025, November). Alcohol Clinical Trials Initiative (ACTIVE). (Virtual presentation).
- *Treatment of Alcohol Withdrawal and Frontiers in Alcohol Use Disorder Treatment.* (2026, May). Research Society on Alcohol Continuing Education Curriculum: Evidence-Based Treatment Approaches. (Virtual presentation: <https://app.tpn.health/education/evidence-based-treatment-approaches-5b2d4da4/>).

Regional

- *From brain to behavior: Neuroimaging and mental illness.* (2012, October). Mental Wellness Partnership, Spartanburg Regional Healthcare System, Spartanburg, SC.
- *Of medicines and magnets: New directions in treatment development for Alcohol Use Disorder.* (2022, January). Clinical Psychology Professional Development Seminar, Department of Psychology and Neuroscience, University of Colorado, Boulder, CO.

Local

- *Hierarchical linear modeling for fMRI analysis.* (2010, October). Center for Advanced Imaging Research, Medical University of South Carolina.
- *Medication effects on alcohol cue-elicited brain activation.* (2011, May). Imaging Group Lecture Series, Center for Biomedical Imaging, Medical University of South Carolina.
- *Functional neuroimaging in addiction.* (2012, February). Neuropsychology Seminar Series, Medical University of South Carolina.

- *Alcohol craving in the brain: Neuroimaging and pharmacological manipulation.* (2013, October). Grand Rounds, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina.
- *Neuroimaging and medications development for Alcohol Use Disorder.* (2016, June). 29th Annual Update in Psychiatry, Medical University of South Carolina.
- *A pilot study of DNA methylation as a pharmacogenetic predictor of treatment response in AUD.* (2018, January). Center for Genomic Medicine Retreat, Medical University of South Carolina.
- *Does nicotine use affect the efficacy of naltrexone in Alcohol Use Disorder?* (2018, May). Tobacco Research Interest Group, Hollings Cancer Center, Medical University of South Carolina.
- *Counseling techniques for primary care: Motivational enhancement.* (2018, November). Project ECHO (Extension for Community Healthcare Outcomes) Opioid Use Disorder Tele-Mentoring Sessions, Medical University of South Carolina.
- *Of medicines and magnets: New directions in treatment development for Alcohol Use Disorder.* (2019, May). Center for Biomedical Imaging Lecture Series, Medical University of South Carolina.
- *Of medicines and magnets: New directions in treatment development for Alcohol Use Disorder.* (2022, May). Research Seminar, Department of Anesthesiology, University of Colorado Anschutz.
- *Pharmacological modulation of dopaminergic neurotransmission in Alcohol Use Disorder: Progress towards personalized medicine.* (2022, September). Neuroscience Graduate Program, University of Colorado Anschutz.
- *Pharmacological modulation of dopaminergic neurotransmission in Alcohol Use Disorder: Progress towards personalized medicine.* (2023, March). Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz.
- *Addiction is a brain disease.* (2023, September). TED for your Head, Neuroscience Innovation Initiative, University of Colorado Anschutz.
- *Research in the Translational Addiction Imaging Laboratory.* (2023, October). Department of Psychiatry Research Retreat, University of Colorado Anschutz.
- *Update on Pharmacotherapy for Alcohol Use Disorder.* (2025, June). Grand Rounds, Department of Psychiatry, University of Colorado Anschutz.
- *Can Ozempic make you drink less? GLP-1: The new miracle molecule.* (2025, December). UCHHealth Board of Directors, University of Colorado Anschutz.
- *From hype to hope: GLP-1 receptor agonists for Alcohol Use Disorder.* (2026, April). Transforming Healthcare Lecture Series, University of Colorado Anschutz.

- *From hype to hope: GLP-1 receptor agonists for Alcohol Use Disorder*. (2026, August). Ludeman Family Center for Women's Health Research, University of Colorado Anschutz.

12. Teaching record

Post-doctoral Students

Medical University of South Carolina

- 2014 NIMH T32 Child and Adult Trauma Training Program
- *Neuroimaging in Clinical Research*, March 2014

Graduate Students

University of Colorado, Boulder

- 2004-2006 Department of Psychology and Neuroscience
- *PSYC 3313: Psychopathology*, Fall 2005, Spring 2006, & Fall 2006
 - *PSYC 4684: Developmental Psychology*, Fall 2004 & Spring 2005

University of Colorado Anschutz School of Medicine

- 2020 NRSC 7614: Biological Basis of Psychiatric and Neurological Disorders
- *Neurobiology of Addiction: Perspectives from Neuroimaging*, March 2020
- 2024 Neuroscience Ph.D. Program Journal Club
- *Faculty discussant*, Lauren Sarabia, September 2024

House Officers

Medical University of South Carolina

- 2012-2018 Psychiatry PGY-3 Seminar Series
- *Motivational Interviewing for Substance Use Disorders*, October 2012, November 2013, October 2014, October 2015, October 2016, December 2017, November 2018
 - *Pharmacogenetics of Alcohol Use Disorder Treatment*, March 2017
- 2012-2019 Psychiatry PGY-2 Seminar Series
- *Neurobiology of Addiction*, February 2012, February 2013, February 2014, January 2015, February 2016, March 2017, March 2018, February 2019
- 2012-2019 Addiction Psychiatry Fellowship
- *Introduction to Neuroimaging*, August 2012, November 2013, April 2016, December 2016, October 2017, March 2019
- 2013-2014 NIDA R25 DART Psychiatry Residency Research Training Program for Physician-Scientists
- *Neuroimaging in Psychiatry*, October 2013, December 2014

University of Colorado Anschutz School of Medicine

- 2020 Addiction Psychiatry Fellowship
- *Neuroimaging in Addiction*, October 2020
- 2020 Child Psychiatry Fellowship
- *Genetics of Substance Use and Risk in Adolescents*, October 2020
- 2021-2025 Psychiatry PGY-1 Seminar Series

- *Neuroscience: Circuits and Cells*, January 2021, April 2021, June 2022, June 2023, June 2024, June 2025, August 2025

2024-2025 Psychiatry PGY-2 Seminar Series

- *Genetics in Psychiatry I and II*, May 2024, May 2025, July 2025, July 2026

Medical Students

Medical University of South Carolina

2015-2019 First-year medical student curriculum

- *Brain Dissection*, Fall 2015, Spring 2016, Fall 2016, Spring 2017, Spring 2018, Fall 2019

University of Colorado Anschutz School of Medicine

2023-2025 First-year medical student Mind & Behavior Course

- *Practice of Motivational Interviewing*
May 2023 (group facilitator)
April 2024, May 2025, May 2026 (coordinator, lecturer, and group facilitator)

Undergraduate Students

University of Michigan, Ann Arbor

2002 Department of Psychology

- *PSYC 114: Honors Introduction to Psychology*, Spring 2002

College of Charleston

2011-2012 Department of Psychology,

- *PSYC 333: Health Psychology*, Fall 2011, Spring 2012, & Fall 2012

University of South Carolina

2012 Department of Psychology

- *PSYC 420: Developmental Psychology: Adolescence, Emerging Adulthood, and the Surfacing of Psychopathology*, July 2012

Mentorship

<u>Years</u>	<u>Mentee</u>	<u>Mentored Position</u>	<u>Current Position</u>
2014-2015	Stephen Boyd, MA	Pre-doctoral intern	Assistant Professor, Oregon Health & Science University
2015-2018	Lindsay Meredith, BA	Research assistant	Post-doc, MUSC
2016-2018	Kelsey Gnade, BA	Research assistant	Pediatric psychologist, Kennedy Krieger Institute
2017-present	Hollis Karoly, PhD *Received ACNP travel award, NIAAA R21 and R01 under my mentorship	Pre-doctoral intern, junior faculty	Associate Professor, CU
2017-2019	Daniel Lench, BA	PhD student (Dissertation committee)	Assistant Professor, MUSC

2018	Andrew Kern, BS	Summer MD student	Medicine/psychiatry resident, MUSC
2019	Andrew Rowley, BS	NIDA R25 student	Diagnostic radiology resident, University of Tennessee
2018-2021	Katy Fuqua, BA	Research assistant	Regulatory Affairs Manager, Lowcountry Center for Veterans Research
2019-present	Joshua Gowin, PhD *Received NIAAA R21, R01 under my mentorship	Junior faculty	Associate Professor, CU
2019-2024	Kate Mitchell, MPH *Received MPH while in my lab	Research coordinator	Sr. clinical research coordinator, Neurona Therapeutics
2019-present	Rachel Baechtold, MA	Research coordinator	Research coordinator, CU
2021-present	Robert Shelton, MS	Research coordinator	Research coordinator, CU
2021-2023	Erin Moe, B.A., PgC	Research coordinator	Research coordinator, CU
2022-2023	Matthew Kubicki, MD	Psychiatry resident	Addiction psych fellow, CU
2022-2025	Melina Kilen, BA	Research coordinator	Research coordinator, CU
2022-2026	Morgan Zipperly, MD, PhD	NIMH R25 resident	Psychiatry resident, CU
2022-present	Dale Terasaki, MD *Received Denver Health pilot grant, Clinical Faculty Scholars Program under my mentorship	Junior faculty	Asst. Prof, Denver Health
2023-2024	Grace Blake, BS	Research coordinator	PA student, George Washington University
2023-present	Drew Winters, PhD *Received ACNP travel award, NIMH K23 under my mentorship	Post-doctoral fellow, Junior faculty	Assistant Professor, CU
2023-2025	Hannah Gebhardt, BA	Research coordinator	PhD student, U. Maine
2023-2026	Hope Nielsen, BA	Research coordinator	Research coordinator, CU
2024-present	Emma Shaffer, BS	Research coordinator	Research coordinator, CU
2024-2025	Anne Williams, BS *Mentored through CU PIKE-PREP program for URM post-bacs	NIGMS R25 post-bac	Behavioral health technician, Denver Health
2024-2016	Jaedyn Birchmier, BS	Research coordinator	MD student, CU Anschutz

2024-present	Leslie Barnard, PhD	Junior faculty	Asst. Prof, Colorado School of Public Health
2025-present	Lauren Sarabia, MS	PhD student (Dissertation committee)	PhD student, CU
2025-present	Zoe Panchal, MD	Post-doctoral fellow, Junior faculty	Post-doctoral fellow, CU
2026	Emma Newton, BA	MS rotation student	MS student, Pharmaceutical Sciences, CU
2026-present	Theodore Libby, BA	Research coordinator	Research coordinator, CU
2026-present	Sam Melendez, MA	PhD student (Dissertation committee)	PhD student, CU-Boulder

13. Grant support

Active

Federal

- NIAAA 75N94025F00002. *Alcohol Cue Human Laboratory Study Testing Apremilast.*
Role: Principal investigator
Dates: 09/2025-11/2026
Percent effort: 20%
Total direct costs = \$439,011
- NIAAA R01 AA031664. *Effects of full-spectrum cannabidiol on alcohol consumption and alcohol use disorder phenotypes: implications for precision medicine.*
Role: Co-investigator (PI: Hollis Karoly)
Dates: 09/2025-08/2029
Percent effort: 15%
Total direct costs = \$2,126,367
- NIDA U01 DA064384. *Multi Site Randomized Trial of a GLP-1/GIP Receptor Agonist for Smoking Cessation.*
Role: Multiple principal investigator (MPIs: Christian Hendershot, Andrea King, & Sherry McKee)
Dates: 07/2025-03/2028
Percent effort: 20%
Total direct costs = \$6,559,122
- NIAAA 75N94021D00016. *NIAAA Medications Development Clinical Investigations Network for the Treatment of Alcohol Use Disorder – Clinical Sites.*
Role: Principal investigator
Dates: 05/2025-05/2028
Percent effort: 2.5%
Total direct costs = \$29,497

- NIDA P50 DA056408. Rocky Mountain Cannabis Research Center Project 2. *Cannabidiol and Cannabis Concentrate Users: A Randomized, Placebo Controlled Study*. (Center PI: Kent E. Hutchison).
Role: Co-principal investigator (Co-PI: L. Cinnamon Bidwell)
Dates: 09/2023-06/2028
Percent effort: 15%
Total direct costs for project = \$1,493,563
- NIAAA R01 AA031244. *Neural Signature Changes Across Early Abstinence in Alcohol Use Disorder*.
Role: Co-investigator (PI: Joshua Gowin)
Dates: 09/2024-05/2029
Percent effort: 5%
Total direct costs = \$1,798,842
- NIAAA R01 AA030483. *Predictive Power of PEth for HIV Prevention in the Long-Acting Era*.
Role: Co-investigator (PI: Jennifer J. Kiser)
Dates: 09/2022-08/2027
Percent effort: 5%
Total direct costs = \$2,146,036
- NIAAA R01 AA029606. *Alcohol Use Disorder and Cannabis: Testing Novel Harm Reduction Strategies*.
Role: Co-investigator (PI: Kent E. Hutchison)
Dates: 04/2022-03/2027
Percent effort: 8%
Total direct costs = \$1,903,480
- NIAAA R01 AA027765. *A pharmacogenetic human laboratory investigation of brexpiprazole in Alcohol Use Disorder*.
Role: Principal investigator
Dates: 09/2019-08/2024 (in no-cost extension to 08/2026)
Percent effort: 25%
Total direct costs = \$1,786,101

Foundation

- Hewit Family Foundation. *Evaluating low-intensity focused ultrasound as a treatment for Alcohol Use Disorder*.
Role: Co-principal investigator (Co-PIs: Joseph Sakai and Jody Tanabe)
Dates: 01/2024-12/2026
Percent effort: 0%
Total direct costs = \$375,000

Completed

Federal

- NIAAA R01 AA026859. *COMT inhibition as a potential therapeutic target among individuals with comorbid Alcohol Use Disorder and Attention-Deficit/ Hyperactivity Disorder*.
Role: Principal investigator

Dates: 04/2019-03/2026
 Percent effort: 25%
 Total direct costs = \$1,141,183

- NIAAA R21 AA030837. *Effects of THC on Alcohol Consumption and Neural Correlates of Reward.*
 Role: Co-investigator (MPIs: Joshua Gowin and Hollis Karoly)
 Dates: 03/2024-02/2026
 Percent effort: 5%
 Total direct costs = \$268,391
- Pharmacotherapies for Alcohol and Substance Use Disorders Alliance (PASA) Study Research Planning Program, Congressionally Directed Medical Research Program AS210006-A3. *Evaluating therapeutic potential of glucagon-like peptide 1 (GLP-1) receptor agonists for alcohol use disorder and co-occurring medical conditions.*
 Role: Co-investigator (MPIs: Christian Hendershot and Lorenzo Leggio)
 Dates: 2024-2025
 Percent effort: 0%
 Total direct costs = \$150,000
- NIAAA R21 AA031146. *An exploratory randomized controlled trial of the effects of oral semaglutide on alcohol craving and consumption.*
 Role: Principal investigator
 Dates: 09/2023-08/2025
 Percent effort: 10%
 Total direct costs = \$275,000
- NIAAA 75N94021D00016. *NIAAA Medications Development Clinical Investigations Network for the Treatment of Alcohol Use Disorder – Clinical Sites.*
 Role: Co-investigator (PI: Kent E. Hutchison)
 Dates: 03/2021-03/2025
 Percent effort: 5%
 Total direct costs = \$90,246
- NIAAA 75N94021F00002. *Alcohol Cue Human Laboratory Study Testing ASP-8062.*
 Role: Principal investigator
 Dates: 09/2021-06/2023
 Percent effort: 25%
 Total direct costs = \$326,004
- NIAAA R01 AA028503. *Sex differences in risk for Alcohol Use Disorder: Neural and hormonal influences.*
 Role: Consultant (PI: Jessica Weafer).
 Dates: 2020
 Percent effort: 0%
 Total direct costs = \$2,500
- NIAAA P50 AA010761. *Charleston Alcohol Research Center Research Component 2. Effects of Cortical Dopamine Regulation on Drinking, Craving, and Cognitive Control.* (Center PI: Howard C. Becker).

Role: Research component co-principal investigator (Co-PI: Raymond F. Anton)
 Dates: 01/2016-12/2020
 Percent effort: 30%
 Total direct costs for component = \$724,870

- NIAAA HHSN271201500004I. *Human Laboratory Paradigms Testing ANS-6637*.
 Role: Principal investigator
 Dates: 09/2018-01/2020
 Percent effort: 30%
 Total direct costs = \$433,912
- NIAAA R00 AA021419. *Neural Connectivity and the Transition to Alcohol Dependence*.
 Role: Principal investigator
 Dates: 09/2015-08/2019
 Percent effort: 70%
 Total direct costs = \$499,584
- NIAAA R21 AA026129. *A human laboratory study of N-acetylcysteine for Alcohol Use Disorder*.
 Role: Consultant (PI: William W. Stoops).
 Dates: 2018
 Percent effort: 0%
 Total direct costs = \$2,500
- NIAAA HHSN275201500004I. *Human Laboratory Paradigms (HLAB) Development*.
 Role: Co-principal investigator (Co-PI: Raymond F. Anton)
 Date: 09/2015-09/2020
 Percent effort: 1%
 Total direct costs = \$5,000
- NIAAA P50 AA010761-19S1. Administrative Supplement to Promote Collaborative Research on Addiction at NIH. *Comorbidity of Nicotine and Alcohol Use: Basic Mechanisms and Effects of Varenicline*.
 Role: Co-investigator (PI: Howard C. Becker)
 Dates: 07/2014-12/2014
 Percent effort: 0%
 Total direct costs = \$100,000
- NIAAA K99 AA021419. *Neural Connectivity and the Transition to Alcohol Dependence*.
 Role: Principal investigator
 Dates: 09/2013-08/2015
 Percent effort: 100%
 Total direct costs = \$193,897
- NIAAA T32 AA007474. *Training in Alcohol Research*.
 Role: Pre- (2009-2010) and Postdoctoral (2010-2013) Fellow (PI: John J. Woodward)
 Dates: 08/2009-07/2013
 Percent effort: 100%
 Total direct costs = Ph.D./post-doc stipend, health insurance, and travel costs

- NIDA F31 DA021496. *A Transdisciplinary Approach to Cannabis Addiction*.
Role: Principal investigator
Dates: 09/2006-09/2009
Percent effort: 100%
Total direct costs = \$75,993

Industry

- Altimune, Inc. *A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects with Obesity or Overweight*
Role: Site principal investigator
Dates: 04/2025-06/2026
Percent effort: 5%
Total direct costs = \$302,316 (some costs are per patient; assumes we will enroll and complete 10 patients)
- Laboratorio Farmaceutico CT. *Effect of GET-73 on magnetic resonance spectroscopy measure of central glutamate and GABA and fMRI activation in non-treatment-seeking alcohol-dependent individuals*.
Role: Co-principal investigator (Co-PIs: Raymond F. Anton and James J. Prisciandaro)
Dates: 2018-2020
Percent effort: 10%
Total direct costs = \$308,519

Foundation

- Hewit Family Foundation. *Supplement to an exploratory randomized controlled trial of the effects of oral semaglutide on alcohol craving and consumption*.
Role: Principal investigator
Dates: 09/2023-08/2025
Percent effort: 0%
Total direct costs = \$100,000
- Anonymous donor. *Effects of oral semaglutide on alcohol and food cue-elicited brain activation*.
Role: Principal investigator
Dates: 09/2023-08/2025
Percent effort: 0%
Total direct costs = \$105,186
- Anonymous donor. *Alcohol Use Disorder Fellowship Fund (support for post-doctoral fellow in the Translational Addiction Imaging Laboratory)*.
Role: Principal investigator
Dates: 08/2023-07/2025
Percent effort: 0%
Total direct costs = \$90,000
- Anonymous donor. *Alcohol Use Disorder Research Fund*.
Role: Principal investigator
Dates: 01/2023-12/2023
Percent effort: 0%

Total direct costs = \$60,038

Internal

- MUSC Center for Genomic Medicine Pilot Grant. *A pilot study of DNA methylation as a pharmacogenetic predictor of treatment response in AUD.*
 Role: Principal investigator
 Dates: 12/2017-11/2018
 Percent effort: 0%
 Total direct costs = \$75,000
- NIAAA P50 AA010761. Charleston Alcohol Research Center Pilot Project. *Resting State Neural Connectivity and GABA/Glutamate Balance in Alcohol Dependence.*
 Role: Co-principal investigator (Co-PI: James J. Prisciandaro).
 Dates: 01/2013-12/2013
 Percent effort: 0%
 Total direct costs = \$25,000

14. Bibliography

Papers published in peer-reviewed journals ($n = 53$; Google Scholar h -index = 28)

*indicates a mentee

1. Haughey, H. M., Marshall, E., **Schacht, J. P.**, Louis, A., & Hutchison, K. E. (2008). Marijuana withdrawal and craving: Influence of the *CNR1* and *FAAH* genes. *Addiction*, 103, 1678-1686. doi: 10.1111/j.1360-0443.2008.02292.x
2. Hutchison, K. E., Haughey, H., Niculescu, M., **Schacht, J.**, Kaiser, A., Stitzel, J., Horton, W. J., & Filbey, F. (2008). The incentive salience of alcohol: Translating the effects of genetic variant in *CNR1*. *Archives of General Psychiatry*, 65, 841-850. doi: 10.1001/archpsyc.65.7.841
3. **Schacht, J. P.**, Selling, R., & Hutchison, K. E. (2009). Intermediate cannabis dependence phenotypes and the *FAAH* C385A variant: An exploratory analysis. *Psychopharmacology (Berl.)*, 203, 511-517. doi: 10.1007/s00213-008-1397-z
4. Filbey, F. M., **Schacht, J. P.**, Myers, U. S., Chavez, R. S., & Hutchison, K. E. (2009). Marijuana craving in the brain. *Proceedings of the National Academy of Sciences USA*, 106, 13016-13021. doi: 10.1073/pnas.0903863106
5. Filbey, F. M., **Schacht, J. P.**, Myers, U. S., Chavez, R. S., & Hutchison, K. E. (2010). Individual and additive effects of the *CNR1* and *FAAH* genes on brain response to marijuana cues. *Neuropsychopharmacology*, 35, 967-975. doi: 10.1038/npp.2009.200
6. **Schacht, J. P.**, Randall, P. K., Waid, L. R., Baros, A. M., Latham, P. K., Wright, T. M., Myrick, H., & Anton, R. F. (2011). Neurocognitive performance, alcohol withdrawal, and effects of a combination of flumazenil and gabapentin in alcohol dependence. *Alcoholism: Clinical & Experimental Research*, 35, 2030-2038. doi: 10.1111/j.1530-0277.2011.01554.x
7. **Schacht, J. P.**, Anton, R. F., Randall, P. K., Li, X., Henderson, S., & Myrick, H. (2011). Stability of fMRI striatal response to alcohol cues: A hierarchical linear modeling approach. *NeuroImage*, 56, 61-68. doi: 10.1016/j.neuroimage.2011.02.004

8. **Schacht, J. P.**, Hutchison, K. E., & Filbey, F. M. (2012). Associations between cannabinoid receptor-1 (*CNR1*) variation and hippocampus and amygdala volumes in heavy cannabis users. *Neuropsychopharmacology*, 37, 2368-2376. doi: 10.1038/npp.2012.92
9. **Schacht, J. P.**, Anton, R. F., Voronin, K. E., Randall, P. K., Li, X., Henderson, S., & Myrick, H. (2013). Interacting effects of naltrexone and *OPRM1* and *DAT1* variation on the neural response to alcohol cues. *Neuropsychopharmacology*, 38, 414-422. doi: 10.1038/npp.2012.195
10. **Schacht, J. P.**, Anton, R. F., & Myrick, H. (2013). Functional neuroimaging studies of alcohol cue reactivity: A quantitative meta-analysis and systematic review. *Addiction Biology*, 18, 121-133. doi: 10.1111/j.1369-1600.2012.00464.x
11. **Schacht, J. P.**, Anton, R. F., Randall, P. K., Li, X., Henderson, S., & Myrick, H. (2013). Effects of a GABA-ergic medication combination and initial alcohol withdrawal severity on cue-elicited brain activation among treatment-seeking alcoholics. *Psychopharmacology (Berl.)*, 227, 627-637. doi: 10.1007/s00213-013-2996-x
12. **Schacht, J. P.**, Anton, R. F., Randall, P. K., Li, X., Henderson, S., & Myrick, H. (2014). Varenicline effects on drinking, craving and neural reward processing among non-treatment-seeking alcohol-dependent individuals. *Psychopharmacology (Berl.)*, 231, 3799-3807. doi: 10.1007/s00213-014-3518-1
13. Prisciandaro, J. J., **Schacht, J. P.**, Prescott, A. P., Renshaw, P. F., Brown, T. R., & Anton, R. F. (2016). Associations between recent heavy drinking and dorsal anterior cingulate N-acetylaspartate and glutamate concentrations in non-treatment seeking individuals with alcohol dependence. *Alcoholism: Clinical & Experimental Research*, 40, 491-496. doi: 10.1111/acer.12977
14. Courtney, K. E., **Schacht, J. P.**, Hutchison, K. E., Roche, D. J. O., & Ray, L. A. (2016). Neural substrates of cue reactivity: Association with treatment outcomes and relapse. *Addiction Biology*, 21, 3-22. doi: 10.1111/adb.12314
15. Boyd, S. J.*, **Schacht, J. P.**, Prisciandaro, J. J., Voronin, K., & Anton, R. F. (2016). Alcohol-induced stimulation mediates the effect of a *GABRA2* SNP on alcohol self-administrated among alcohol-dependent individuals. *Alcohol and Alcoholism*, 51, 549-554. doi: 10.1093/alcalc/agw024
16. Adams, Z. W., **Schacht, J. P.**, Randall, P., & Anton, R. F. (2016). The Reasons for Heavy Drinking Questionnaire: Factor structure and validity in alcohol-dependent adults involved in clinical trials. *Journal of Studies on Alcohol and Drugs*, 77, 354-361. doi: 10.15288/jsad.2016.77.354
17. **Schacht, J. P.** (2016). *COMT* val158met moderation of dopaminergic drug effects on cognitive function: A critical review. *The Pharmacogenomics Journal*, 16, 430-438. doi: 10.1038/tpj.2016.43
18. Anton, R. F., **Schacht, J. P.**, Voronin, K. E., Randall, P. K. (2017). Aripiprazole suppression of drinking in a clinical laboratory paradigm: Influence of impulsivity and self-control. *Alcoholism: Clinical & Experimental Research*, 41, 1370-1380. doi: 10.1111/acer.13417

19. **Schacht, J. P.**, Randall, P. K., Latham, P. K., Voronin, K. E., Book, S. W., Myrick, H., & Anton, R. F. (2017). Predictors of naltrexone response in a randomized trial: Reward-related brain activation, *OPRM1* genotype, and smoking status. *Neuropsychopharmacology*, *42*, 2640-2653. doi: 10.1038/npp.2017.74
20. Nguyen-Louie, T. T., Simmons, A. N., Squeglia, L. M., Infante, A. M., **Schacht, J. P.**, & Tapert, S. F. (2018). Earlier alcohol use onset prospectively predicts changes in functional connectivity. *Psychopharmacology*, *235*, 1041-1054. doi: 10.1007/s00213-017-4821-4
21. Anton, R. F., Latham, P. K., Voronin, K. E., Randall, P. K., Book, S. W., Hoffman, M., & **Schacht, J. P.** (2018). Nicotine use/smoking is associated with the efficacy of naltrexone in the treatment of alcohol dependence. *Alcoholism: Clinical & Experimental Research*, *42*, 751-760. doi: 10.1111/acer.13601
22. **Schacht, J. P.**, Voronin, K. E., Randall, P. K., & Anton, R. F. (2018). Dopaminergic genetic variation influences aripiprazole effects on alcohol self-administration and the neural response to alcohol cues in a randomized trial. *Neuropsychopharmacology*, *43*, 1247-1256. doi: 10.1038/npp.2017.298
23. Prisciandaro, J. J., **Schacht, J. P.**, Prescott, A. P., Renshaw, P. F., Brown, T. R., & Anton, R. F. (2019). Brain glutamate, GABA, and glutamine levels and associations with recent drinking in treatment naïve individuals with Alcohol Use Disorder versus light drinkers. *Alcoholism: Clinical & Experimental Research*, *43*, 221-226. doi: 10.1111/acer.13931
24. **Schacht, J. P.**, Anton, R. F., McNamara, P. J., Im, Y., & King, A. C. (2019). The dopamine transporter VNTR polymorphism moderates the relationship between acute response to alcohol and future Alcohol Use Disorder symptoms. *Addiction Biology*, *24*, 1109-1118. doi: 10.1111/adb.12676
25. Prisciandaro, J. J., **Schacht, J. P.**, Prescott, A. P., Brenner, H. M., Renshaw, P. F., Brown, T. R., & Anton, R. F. (2019). Evidence for a unique association between fronto-cortical glycine levels and recent heavy drinking in treatment-naïve individuals with Alcohol Use Disorder. *Neuroscience Letters*, *706*, 207-210. doi: 10.1016/j.neulet.2019.05.030
26. Karoly, H. C.*, **Schacht, J. P.**, Meredith, L. R., Jacobus, J., Tapert, S. F., Gray, K. M., & Squeglia, L. M. (2019). Investigating a novel fMRI cannabis cue reactivity task in youth. *Addictive Behaviors*, *89*, 20-28. doi: 10.1016/j.addbeh.2018.09.015
27. Karoly, H. C.*, **Schacht, J. P.**, Jacobus, J., Meredith, L. R., Taylor, C. T., Tapert, S. F., Gray, K. M., & Squeglia, L. M. (2019). Preliminary evidence that computerized approach avoidance training is not associated with changes in fMRI cannabis cue reactivity in non-treatment-seeking adolescent cannabis users. *Drug and Alcohol Dependence*, *200*, 145-152. doi: 10.1016/j.drugalcdep.2019.04.007
28. Hartwell, E. E., Feinn, R., Morris, P., Gelernter, J., Krystal, J., Arias, A. J., Hoffman, M., Petrakis, I., Gueorguieva, R., **Schacht, J. P.**, Oslin, D., Anton, R. F., & Kranzler, H. R. (2020). Systematic review and meta-analysis of the moderating effect of rs1799971 in *OPRM1*, the mu-opioid receptor gene, on response to naltrexone treatment of Alcohol Use Disorder. *Addiction*, *115*, 1426-1437. doi: 10.1111/add.14975

29. Prisciandaro, J. J., **Schacht, J. P.**, Prescott, A. P., Brenner, H. M., Renshaw, P. F., Brown, T. R., & Anton, R. F. (2020). Intraindividual changes in brain GABA, glutamate, and glutamine levels following short-term monitored abstinence from alcohol in treatment-naïve individuals with Alcohol Use Disorder and light drinkers. *Addiction Biology*, 25, e12810. doi: 10.1111/adb.12810
30. Anton, R. F., Voronin, K. E., Book, S. W., Latham, P. K., Randall, P. K., Glen, W. B., Hoffman, M., & **Schacht, J. P.** (2020). Opioid and dopamine genes interact to predict naltrexone response in a randomized Alcohol Use Disorder clinical trial. *Alcoholism: Clinical & Experimental Research*, 44, 2084-2096. doi: 10.1111/acer.14431
31. Burnette, E. M., Grodin, E. N., **Schacht, J. P.**, & Ray, L. A. (2021). Clinical and neural correlates of reward and relief drinking. *Alcoholism: Clinical & Experimental Research*, 45, 194-203. doi: 10.1111/acer.14495
32. Ellingson, J. M., Hinckley, J. D., Ross, J. M., **Schacht, J. P.**, Bidwell, L. C., Bryan, A. D., Hopfer, C. J., Riggs, P., & Hutchison, K. E. (2021). The Neurocognitive Effects of Cannabis Across the Lifespan. *Current Behavioral Neuroscience Reports*, 8, 124-133. doi: 10.1007/s40473-021-00244-7
33. Ekhtiari H., ... **Schacht, J.P.**, et al. (2022). A methodological checklist for fMRI drug cue reactivity studies: development and expert consensus. *Nature Protocols*, 17, 567-595. doi: 10.1038/s41596-021-00649-4
34. **Schacht, J. P.**, Hoffman, M., Chen, B. H., & Anton, R. F. (2022). Epigenetic moderators of naltrexone efficacy in reducing heavy drinking in Alcohol Use Disorder: A randomized trial. *The Pharmacogenomics Journal*, 22, 1-8. doi: 10.1038/s41397-021-00250-8
35. **Schacht, J. P.**, Hoffman, M., Im., Y., Voronin, K. E., Book, S. W., & Anton, R. F. (2022). Effects of pharmacological and genetic regulation of COMT signaling in Alcohol Use Disorder: A randomized, placebo-controlled trial of tolcapone. *Neuropsychopharmacology*, 47, 1953-1960. doi: 10.1038/s41386-022-01335-z
36. Leggio, L., Hendershot, C. S., Farokhnia, M., Fink-Jensen, A., Klausen, M. K., **Schacht, J. P.**, Simmons, W. K. (2023). GLP-1 receptor agonists are promising, but unproven treatments for alcohol and substance use disorders. *Nature Medicine*, 29, 2993-2995. doi: 10.1038/s41591-023-02634-8
37. **Schacht, J. P.**, Kubicki, M.*, & Anton, R. F. (2024). A randomized trial of the effects of COMT inhibition on subjective response to alcohol: Moderation by baseline COMT activity and mediation of alcohol self-administration. *Alcohol: Clinical & Experimental Research*, 48, 178-187. doi: 10.1111/acer.15227
38. Sangchooli, A., Zare-Bidoky, M., Jouzdani, A. F., **Schacht, J.**, ... Ekhtiari, H. (2024). Parameter Space and Potential for Biomarker Development in 25 Years of fMRI Drug Cue Reactivity: A Systematic Review. *JAMA Psychiatry*, 81, 414-425. doi: 10.1001/jamapsychiatry.2023.5483
39. Karoly, H. C.*, Kirk-Provencher, K. T., **Schacht, J. P.**, & Gowin, J. L.* (2024). Alcohol and Brain Structure Across the Lifespan: A Systematic Review of Large-Scale Neuroimaging Studies. *Addiction Biology*, 29, e13439. doi: 10.1111/adb.13439

40. **Schacht, J. P.**, Ray, L. A., Miranda Jr., R., Falk, D. E., Ryan, M. L., Sakai, J. T., Miotto, K., Chun, T., Scott, C., Ransom, J., Alsharif, N., Ito, M., & Litten, R. Z. (2024). Effects of a novel GABA-B positive allosteric modulator, ASP8062, on alcohol cue-elicited craving and naturalistic alcohol consumption in a multisite randomized, double-blind, placebo-controlled trial. *Alcohol: Clinical & Experimental Research*, 48, 2352-2363. doi: 10.1111/acer.15468
41. Ekhtiari, H., Sangchooli, A., Carmichael, O., Moeller, F. G., O'Donnell, P., Oquendo, M., Paulus, M. P., Pizzagalli, D. A., Ramey, T., **Schacht, J. P.**, Zare-Bidoky, M., Childress, A. R., & Brady, K. (2024). Neuroimaging biomarkers of addiction. *Nature Mental Health*, 2, 1498-1517. doi: 10.1038/s44220-024-00334-x
42. O'Malley, S. S., Miranda, Jr., R., Book, S., Chun, T., Liss, T., Malcolm, R., Muvvala, S., Treloar Padovano, H., **Schacht, J. P.**, Blackburn, B., Diamond, I., Ransom, J., Ryan, M., Falk, D., & Litten, R. Z. (2025). Preliminary Effects of Oral ANS-6637, an ALDH2 Inhibitor, on Cue-Induced Craving, Safety and Efficacy among Adults with Alcohol Use Disorder: A Proof-of-Concept, Randomized, Human Laboratory Trial. *Alcohol and Alcoholism*, 60, agaf001. doi: 10.1093/alcac/agaf001
43. Terasaki, D.*, Frank, J. & **Schacht, J.** (2025). Chronic pain associated alcohol use disorder among participants in a small clinical trial. *Journal of Addiction Medicine*, 19, 236-237. doi: 10.1097/ADM.0000000000001393
44. Prisciandaro, J., **Schacht, J. P.**, Prescott, A., & Anton, R. (2025). Brain Glutathione Levels and Associations with Recent Drinking in Treatment-Naïve Individuals with Alcohol Use Disorder Versus Light Drinkers. *Drug and Alcohol Dependence*, 272:112705. doi: 10.1016/j.drugalcdep.2025.112705
45. Kirsch, D. E., McManus, K. R., Grodin, E. N., Nieto, S. J., Miranda, Jr., R., O'Malley, S. S., **Schacht, J. P.**, & Ray, L. A. (2025). Who is alcohol cue-reactive? A machine learning approach. *Alcohol and Alcoholism*, 60: agaf052. doi: 10.1093/alcac/agaf052
46. Winters, D. E.* & **Schacht, J. P.** (2025). Effects of COMT suppression in a randomized trial on the neural correlates of inhibitory processing among individuals with Alcohol Use Disorder. *Biological Psychiatry: Cognitive Neuroscience and Neuroimaging*. doi: 10.1016/j.bpsc.2025.06.003
The journal highlighted this paper with a press release:
<https://www.elsevier.com/about/press-releases/new-study-identifies-novel-neural-pathway-to-treat-alcohol-use-disorder>
47. Kirsch, D. E., Grodin, E. N., Leggio, L., McKee, S. A., Meredith, L. R., Mereish, E. H., Miranda Jr, R., Nieto, S. J., O'Malley, S. S., **Schacht, J. P.**, & Ray, L. A. (2025). The alcohol cue-exposure paradigm as a screening tool for alcohol use disorder medication development: A critical review. *Alcohol: Clinical & Experimental Research*, 49, 2412-2426. doi: 10.1111/acer.70170
48. Barnard, L. M.*, Rosenberg, S., Brooks-Russell, A., Betz, M. E., & **Schacht, J. P.** (2025). Alcohol use, risk of suicide, and access to firearms among youth in Colorado. *Cogent Mental Health*, 5, 2607769. doi: 10.1080/28324765.2025.2607769

49. Tanabe, J., Hickman, J., Tekriwal, A., Sakai, J., Abosch, A., Ojemann, S., **Schacht, J. P.**, & Thompson, J. A. (2026). Electrophysiology and functional MRI of cue craving: potential biomarkers for therapeutic neuromodulation in addiction. *Biological Psychiatry: Global Open Science*, 6, 100622. doi: 10.1016/j.bpsgos.2025.100622
50. Belnap, M. A., Witkiewitz, K., **Schacht, J. P.**, Anton, R. F., Aldridge, A. P., Nieto, S. J., & Ray, L. A. (2026). Examining the impact of trial length on detecting medication effects for alcohol use disorder: A meta-regression study. *Alcohol: Clinical & Experimental Research*, 50, e70306. doi: 10.1111/acer.70306
51. **Schacht, J. P.**, Sakai, J. T., Raymond, K., & Shelton, R. (2026). Oral Semaglutide for Alcohol Use Disorder: A Randomized Clinical Trial. *The American Journal of Psychiatry*. **The journal highlighted this paper with a press release:**
<https://www.psychiatry.org/News-room/News-Releases/New-Research-Oral-Semaglutide-Reduced-Heavy-Drinki>
52. Winters, D. E.*, Spitz, J., Raymond, K., Natvig, C., Waller, R., Mikulich-Gilbertson, S. K., **Schacht, J. P.**, & Sakai, J. T. (in press). Cognitive Control Difficulties Differentiate Callous-Unemotional Traits from Conduct Problems: A Pre-registered Double-blind Randomized Controlled Trial Analysis. *Child Psychiatry and Human Development*. doi: 10.1007/s10578-025-01869-5
53. Pince, C. L., Hetelekides, E., **Schacht, J. P.**, Gowin, J. L., Bidwell, L. C., & Karoly, H. C. (in press). Cannabidiol and Alcohol Use Disorders: An Updated Review of Therapeutic Potential. *Alcohol: Clinical & Experimental Research*.

Book chapters (n = 3)

1. Anton, R. F., **Schacht, J. P.**, & Book, S. W. (2014). Pharmacologic treatment of alcoholism. In E. V. Sullivan & A. Pfefferbaum (Eds.), *Handbook of Clinical Neurology, 3rd series, Volume 125: Alcohol and the Nervous System* (pp. 527-542). Philadelphia: Elsevier. doi: 10.1016/B978-0-444-62619-6.00030-6
2. **Schacht, J. P.** & Hutchison, K. E. (2015). Using clinical neuroscience to understand addiction treatment. In S. W. Feldstein-Ewing, K. Witkiewitz, & F. M. Filbey (Eds.), *Neuroimaging and Psychosocial Addiction Treatment: An Integrative Guide for Researchers and Clinicians*. London: Palgrave Macmillan. doi:10.1057/9781137362650_3
3. Gowin, J. L.*, Kirk-Provencher, K. T., Karoly, H. C.*, & **Schacht, J. P.** (2023). Structural and functional imaging of alcohol's effects on the brain. In M. Heilig & S. Mueller (Eds.), *Alcohol and Alcohol-Related Diseases* (pp. 475-491). Berlin: Springer Nature. doi:10.1007/978-3-031-32483-3_26

Invited commentary (n = 4)

1. **Schacht, J. P.** (2018). Parsing cannabis exposure and predisposing risk effects: Does adolescent cannabis use cause neurocognitive impairment, or result from it? *Biological Psychiatry: Cognitive Neuroscience and Neuroimaging*, 3, 654-656. doi: 10.1016/j.bpsc.2018.06.005
2. Bartels, K., & **Schacht, J. P.** (2021). Cocaine-positive patients undergoing elective surgery – from avoiding case cancellations to treating substance use disorders. *Anesthesia & Analgesia*, 132, 305-307. doi: 10.1213/ANE.0000000000004969

3. **Schacht, J. P.** (2024). Stress, cues, and craving: Does the insula hold the key to understanding stress-induced drinking in Alcohol Use Disorder? *Biological Psychiatry*, 95, 200-201. doi: 10.1016/j.biopsych.2023.10.022
4. Bernstein, E. Y., & **Schacht, J. P.** (2025). Distilling the evidence for GLP-1 receptor agonists in alcohol use disorder. *Addiction Science & Clinical Practice*, 20, 98. doi: 10.1186/s13722-025-00638-y

Other publications (n = 1)

1. **Schacht, J.P.** (2024). Alcohol use disorder can be treated by an array of medications – but few people have heard of them. *The Conversation*. doi: [10.64628/AAI.df5jxxpva](https://doi.org/10.64628/AAI.df5jxxpva)

Scientific abstracts published or presented at scientific meetings (first and senior author only)

Competitive

Oral/podium presentations

1. **Schacht, J. P.,** Anton, R. F., Randall, P. K., Li, X., Henderson, S., & Myrick, H. (2010, June). *Stability of fMRI response to alcohol cues: A repeated study among non-treatment-seeking alcoholics*. Paper and poster presented at the 33rd Annual Meeting of the Research Society on Alcoholism, San Antonio, TX.
2. **Schacht, J. P.,** Anton, R. F., & Myrick, H. (2011, September). *Functional neuroimaging studies of alcohol cue reactivity: A quantitative meta-analysis*. Paper presented at the 2011 NIAAA Training Directors Meeting, Providence, RI.
3. **Schacht, J. P.,** Anton, R. F., Randall, P. K., Li, X., Henderson, S., & Myrick, H. (2012, June). *Interacting effects of naltrexone and OPRM1 and DAT variation on the neural response to alcohol cues*. Symposium presented at the 35th Annual Meeting of the Research Society on Alcoholism, San Francisco, CA.
4. **Schacht, J. P.,** Tabesh, A., Voronin, K. E., & Anton, R. F. (2013, May). *Frontostriatal white matter microstructure and temporal discounting in alcohol dependence*. Symposium presented at the 1st Annual Collaborative Perspectives on Addiction meeting (American Psychological Association, Divisions 28 and 50), Atlanta, GA.
5. **Schacht, J. P.,** Randall, P. K., & Anton, R. F. (2014, June). *Prediction and validation of alcohol dependence severity from neural functional connectivity during alcohol cue exposure*. Symposium, paper, and poster presented at the 37th Annual Meeting of the Research Society on Alcoholism/17th Congress of the International Society for Biomedical Research on Alcoholism, Bellevue, WA.
6. **Schacht, J. P.,** Prisciandaro, J. J., Voronin, K. E., & Anton, R. F. (2015, June). *Multimodal magnetic resonance imaging of neural connectivity in early-stage alcohol dependence: Associations with impulsivity*. Symposium presented at the 38th Annual Meeting of the Research Society on Alcoholism, San Antonio, TX.
7. **Schacht, J. P.,** Voronin, K. E., & Anton, R. F. (2016, February). *Dopaminergic genetic effects on the neural correlates of response inhibition among young adults with Alcohol Use Disorder*. Symposium presented at the 44th Annual Meeting of the International Neuropsychological Society, Boston, MA.

8. **Schacht, J. P.**, Randall, P. K., Latham, P. K., Voronin, K. E., Myrick, H., & Anton, R. F. (2016, September). *Alcohol cues and the ventral striatum: Pharmacogenetic moderation of naltrexone effects and prediction of treatment response*. Symposium presented at the 2016 World Congress on Alcohol and Alcoholism (International Society for Biomedical Research on Alcoholism), Berlin, Germany.
9. **Schacht, J. P.**, Voronin, K. E., Randall, P. K., & Anton, R. F. (2017, June). *Interacting effects of aripiprazole and dopaminergic genetic variation on alcohol self-administration and the neural response to alcohol cues*. Symposium presented at the 40th Annual Meeting of the Research Society on Alcoholism, Denver, CO.
10. **Schacht, J. P.**, Hoffman, M., Voronin, K. E., & Anton, R. F. (2019, June). *Prediction of alcohol harm reduction outcomes from cue-elicited brain activation in a randomized trial of naltrexone*. Symposium presented at the 42nd Annual Meeting of the Research Society on Alcoholism, Minneapolis, MN.
11. **Schacht, J. P.**, Im., Y., Voronin, K. E., & Anton, R. F. (2021, June). *Relationships between peripheral COMT activity, drinking, and cue-elicited brain activation in a human laboratory study of COMT inhibition*. Symposium presented at the 44th Annual Meeting of the Research Society on Alcoholism/20th Congress of the International Society for Biomedical Research on Alcoholism (virtual meeting).
12. **Schacht, J. P.** (2021, December). *Alcohol cue-elicited brain activation as an endophenotype for Alcohol Use Disorder medications development*. Study group talk presented at the 60th Annual Meeting of the American College on Neuropsychopharmacology, San Juan, Puerto Rico.
13. **Schacht, J. P.**, Hoffman, M., Im., Y., Voronin, K. E., & Anton, R. F. (2022, June). *Effects of pharmacological and genetic regulation of COMT signaling in Alcohol Use Disorder: A randomized, placebo-controlled trial of tolcapone*. Symposium presented at the 45th Annual Meeting of the Research Society on Alcoholism, Orlando, FL.
14. **Schacht, J. P.** (2023, June). *Neuroimaging as a Response Biomarker in Drug Development*. Symposium presented at the 85th Annual Meeting of the College on Problems of Drug Development, Denver, CO.
15. **Schacht, J. P.**, Hoffman, M., Chen, B.H., & Anton, R. F. (2023, June). *Epigenetic predictors of naltrexone response in Alcohol Use Disorder*. Symposium presented at the 46th Annual Meeting of the Research Society on Alcohol, Bellevue, WA.
16. **Schacht, J. P.**, Ray, L. A., Miranda Jr., R. Falk, D. E., Ryan, M. L., Sakai, J. T., Miotto, K., Chun, T., Ransom, J., Scott, C., & Litten, R. Z. (2024, June). *Effects of the GABA-B positive allosteric modulator ASP8062 on alcohol craving and consumption in a multisite randomized, double-blind, placebo-controlled trial*. Symposium presented at the 47th Annual Meeting of the Research Society on Alcohol, Minneapolis, MN.
17. **Schacht, J. P.** (2024, September). *Rationale for a randomized controlled trial of oral semaglutide for Alcohol Use Disorder*. Symposium presented at the North American Congress of Clinical Toxicology, Denver, CO.

18. **Schacht, J. P.** (2025, June). *Effects of Semaglutide on Functional Neuroimaging Outcomes in a Randomized Trial for Alcohol Use Disorder*. Roundtable talk presented at the 48th Annual Meeting of the Research Society on Alcohol, New Orleans, LA.
19. **Schacht, J. P.**, Ray, L. A., Miranda Jr., R. Falk, D. E., Ryan, M. L., Sakai, J. T., Miotto, K., Chun, T., Ransom, J., Scott, C., & Litten, R. Z. (2025, September). *GABA-B positive allosteric modulation for Alcohol Use Disorder: A multi-site randomized controlled trial*. Symposium presented at the 2025 Congress of the European Society for Biomedical Research on Alcoholism, Brussels, Belgium.
20. **Schacht, J. P.**, Sakai, J. T., Raymond, K., & Shelton, R. (2026, May). *Oral Semaglutide for Alcohol Use Disorder: A Randomized Clinical Trial*. Symposium presented at the American Psychiatric Association annual meeting, San Francisco, CA.
21. **Schacht, J. P.**, Sakai, J. T., Raymond, K., & Shelton, R. (2026, June). *Oral Semaglutide for Alcohol Use Disorder: A Randomized Clinical Trial*. Symposium presented at the 49th Annual Meeting of the Research Society on Alcohol, San Antonio, TX.

Poster presentations *indicates a mentee

22. **Schacht, J. P.**, Selling, R., & Hutchison, K. E. (2007, June). *The fatty acid amide hydrolase C385A (P129T) variant: Analysis of association with intermediate cannabis dependence phenotypes*. Poster presented at the 37th Annual Meeting of the Behavior Genetics Association, Amsterdam, The Netherlands.
23. **Schacht, J. P.**, & Hutchison, K. E. (2008, June). *Effects of past-month drinking on craving for and response to marijuana*. Poster presented at the 31st Annual Meeting of the Research Society on Alcoholism/14th Congress of the International Society for Biomedical Research on Alcoholism, Washington, D.C.
24. **Schacht, J. P.**, Myers, U., Chavez, R., Hutchison, K. E., & Filbey, F. M. (2009, June). *Marijuana users with comorbid alcohol use disorders respond differently to marijuana cues: An fMRI study*. Poster presented at the 32nd Annual Meeting of the Research Society on Alcoholism, San Diego, CA.
25. **Schacht, J. P.**, Anton, R. F., Randall, P. K., Li, X., Henderson, S., & Myrick, H. (2011, June). *Alcohol cue-elicited activation of the dorsolateral prefrontal cortex: Relationship to relapse drinking during alcohol treatment*. Poster presented at the 34th Annual Meeting of the Research Society on Alcoholism, Atlanta, GA.
26. **Schacht, J. P.**, Hutchison, K. E., & Filbey, F. M. *Associations between cannabinoid receptor-1 (CNRI) variation and amygdala and hippocampus volumes in heavy cannabis users*. (2012, May). Poster presented at the 14th Annual Genes, Brain, and Behavior meeting of the International Behavioural and Neural Genetics Society, Boulder, CO.
27. **Schacht, J. P.**, Tabesh, A., Voronin, K. E., & Anton, R. F. (2012, December). *Diffusional kurtosis imaging of frontal white matter in alcohol-dependent young adults with and without attention deficit hyperactivity disorder*. Poster presented at the 51st Annual Meeting of the American College of Neuropsychopharmacology, Hollywood, FL.
28. **Schacht, J. P.**, Cortese, B. M., Voronin, K. E., & Anton, R. F. (2013, February). *Functional connectivity of the default mode network and temporal discounting of reward in alcoholism*.

Poster presented at the 3rd International Conference on Applications of Neuroimaging to Alcoholism (ICANA-3), New Haven, CT.

29. **Schacht, J. P.**, Cortese, B. M., Voronin, K. E., & Anton, R. F. (2013, June). *Resting state functional connectivity of the default mode network predicts impulsive choice in alcohol dependence*. Poster presented at the 35th Annual Meeting of the Research Society on Alcoholism, Orlando, FL.
30. **Schacht, J. P.**, Anton, R. F., Randall, P. K., Li, X., Henderson, S., & Myrick, H. (2013, December). *Varenicline effects on neural reward processing among non-treatment-seeking alcohol dependent individuals*. Poster presented at the 52nd Annual Meeting of the American College of Neuropsychopharmacology, Hollywood, FL.
31. **Schacht, J. P.**, Randall, P. K., Voronin, K. E., & Anton, R. F. (2014, December). *Variation at the COMT val158met SNP moderates aripiprazole effects on drinking and alcohol cue-elicited activation of the orbitofrontal cortex*. Poster presented at the 53rd Annual Meeting of the American College of Neuropsychopharmacology, Phoenix, AZ.
32. **Schacht, J. P.**, Myrick, H., Latham, P. K., Voronin, K. E., & Anton, R. F. (2015, December). *Effects of DRD4 VNTR genotype on alcohol cue-elicited brain activation among treatment-seeking alcoholics*. Poster presented at the 54th Annual Meeting of the American College of Neuropsychopharmacology, Hollywood, FL.
33. Meredith, L. R. *, Prisciandaro, J. J., Voronin, K. E., Anton, R. F., & **Schacht, J. P.** (2016, June). *Relationships between behavioral impulsivity and white matter microstructure in young adults with alcohol dependence*. Poster presented at the 39th Annual Meeting of the Research Society on Alcoholism, New Orleans, LA.
34. **Schacht, J. P.**, Voronin, K. E., Randall, P. K., & Anton, R. F. (2016, December). *Pharmacogenetic effects of DAT1 variation on aripiprazole response among non-treatment-seeking individuals with Alcohol Use Disorder*. Poster presented at the 55th Annual Meeting of the American College of Neuropsychopharmacology, Hollywood, FL.
35. **Schacht, J. P.**, Anton, R. F., McNamara, P. J., Im, Y., & King, A. C. (2017, December). *The dopamine transporter VNTR polymorphism moderates the relationship between acute response to alcohol and future Alcohol Use Disorder symptoms*. Poster presented at the 56th Annual Meeting of the American College of Neuropsychopharmacology, Palm Springs, CA.
36. Karoly, H. C. *, Anton, R.F., Voronin, K.E. & **Schacht, J.P.** (2018, June). *Examining the effects of aripiprazole on neural network dynamics during an alcohol cue task*. Poster presented at the 41st Annual Meeting of the Research Society on Alcoholism, San Diego, CA.
37. **Schacht, J. P.**, Anton, R. F., McNamara, P. J., Im, Y., & King, A. C. (2018, June). *Effects of DAT1 VNTR genotype on relationships between acute response to alcohol across the BrAC curve and subsequent Alcohol Use Disorder symptoms*. Poster presented at the 41st Annual Meeting of the Research Society on Alcoholism, San Diego, CA.
38. Karoly, H. C. *, Anton, R.F., Voronin, K.E. & **Schacht, J.P.** (2018, December). *Intrinsic Network Coupling During an Alcohol Cue Task: Association with Alcohol-Induced Stimulation and Effects of Aripiprazole*. Poster presented at the 57th Annual Meeting of the American College of Neuropsychopharmacology, Hollywood, FL.

39. **Schacht, J. P.**, Prisciandaro, J. J., & Anton, R. F. (2018, December). *Differential associations between cortical GABA and glutamate and resting-state functional connectivity of the dorsal anterior cingulate cortex in Alcohol Use Disorder*. Poster presented at the 57th Annual Meeting of the American College of Neuropsychopharmacology, Hollywood, FL.
40. **Schacht, J. P.**, Voronin, K. E., Hoffman, M., & Anton, R. F. (2022, December). *Attention-Deficit/Hyperactivity Disorder and self-control moderate effects of the COMT inhibitor tolcapone on alcohol consumption and control-related brain activation*. Poster presented at the 61st Annual Meeting of the American College of Neuropsychopharmacology, Phoenix, AZ.
41. **Schacht, J. P.**, Kubicki, M.*, & Anton, R. F. (2024, January). *A randomized trial of the effects of COMT inhibition on subjective response to alcohol: Moderation by baseline COMT activity and mediation of alcohol self-administration*. Poster presented at the 2024 Winter Conference on Brain Research, Breckenridge, CO.
42. Winters, D. E.* & **Schacht, J. P.** (2024, December). *Effects of COMT inhibition on the neural correlates of inhibitory processing among individuals with Alcohol Use Disorder*. Poster presented at the 63rd Annual Meeting of the American College of Neuropsychopharmacology, Phoenix, AZ.
43. Barnard, L. M.*, Li, K., Brooks-Russell, A., & **Schacht, J.** (2025, June). *Alcohol use and suicide risk among youth in one U.S. state, 2023*. Poster presented at the International Association for Suicide Prevention World Congress, Vienna, Austria.
44. Barnard, L. M.*, Li, K., Brooks-Russell, A., Betz, M. E., & **Schacht, J. P.** (2025, June). *Alcohol Use, Risk of Suicide, and Access to Firearms among Youth in Colorado*. Poster presented at the 48th Annual Meeting of the Research Society on Alcohol, New Orleans, LA.
45. **Schacht, J. P.**, & Winters, D. E.* (2026, January). *Tolcapone Effects on the Neural Substrates of Spatial Working Memory among Individuals with Alcohol Use Disorder*. Poster presented at the 64th Annual Meeting of the American College of Neuropsychopharmacology, Nassau, Bahamas.
46. Barnard, L. M.*, Brooks-Russell, A., Wright-Kelly, E., Stanley, I., & **Schacht, J. P.** (2026, June). *Risk Profiles of Alcohol-Involved Suicides: A Latent Class Analysis of National Violent Death Reporting System Data*. Poster presented at the 49th Annual Meeting of the Research Society on Alcohol, San Antonio, TX.
47. Barnard, L. M.*, Johnson, R. L., Knoepke, C. E., & **Schacht, J. P.** (2026, June). *Alcohol Misuse Treatment Referrals and Arrests among Extreme Risk Protection Order Respondents in Colorado, 2020–2024*. Poster presented at the 49th Annual Meeting of the Research Society on Alcohol, San Antonio, TX.

15. Media Appearances

2016

CBC/Radio-Canada, *The Nature of Things*, January 21, 2016. “Wasted: A Documentary”.
<https://addictionthenextstep.com/documentary/>; <https://www.imdb.com/title/tt10483212/>

2021

Mind the Brain, May 25, 2021. “Dr. Joseph Schacht on the Clinical Neuroscience of Substance Use Disorders”. <https://medschool.cuanschutz.edu/psychiatry/home/media/in-the-news/mind-the-brain/mind-the-brain-dr-joseph-schacht-on-the-clinical-neuroscience-of-substance-use-disorders>

2022

CU Anschutz Newsroom, April 5, 2022. “Surge in Alcohol Deaths Adds Urgency to CU Researcher’s Quest for Medication.” <https://news.cuanschutz.edu/news-stories/surge-in-alcohol-deaths-adds-urgency-to-cu-researchers-quest-for-medication>

KDVR, April 6, 2022. “Clinical trial underway in Colorado to see if new medication can reduce alcohol cravings”. <https://kdvr.com/news/local/clinical-trial-underway-in-colorado-to-see-if-new-medication-can-reduce-alcohol-cravings/>

The Denver Post, April 17, 2022. “Alcohol deaths jumped by nearly 30% in Colorado in 2020 with less treatment, more drinking alone.” <https://www.denverpost.com/2022/04/17/colorado-alcohol-deaths-pandemic/>

CU Anschutz Newsroom, September 21, 2022. “Can Science Curb an Alcohol Use Crisis? CU Anschutz Addiction Experts Bank On It.” <https://news.cuanschutz.edu/news-stories/can-science-curb-an-alcohol-use-crisis-cu-anschutz-addiction-experts-bank-on-it>

SELF Magazine, December 8, 2022. “Why Do I Get Super Anxious the Day After Drinking?” <https://www.self.com/story/anxiety-after-drinking>

2023

CU Anschutz Newsroom, May 4, 2023. “The Under-Discussed Consequence of Alcohol Use Disorder: ‘Wet Brain’.” <https://news.cuanschutz.edu/news-stories/the-under-discussed-consequence-of-alcohol-use-disorder-wet-brain>

NBC News, June 24, 2023. “Researchers keep discovering new uses for Ozempic. Proving it works isn’t easy.” <https://www.nbcnews.com/health/health-news/ozempic-other-health-conditions-pcos-alzheimers-rcna90457>

SELF Magazine, July 6, 2023. “3 Things to Do If You Drank Too Much and Feel Like Garbage.” <https://www.self.com/story/three-things-hangover>

Science, August 28, 2023. “Hot weight loss drugs tested as addiction treatments.” <https://www.science.org/content/article/hot-weight-loss-drugs-tested-addiction-treatments>

KOA 850, September 6, 2023. “CU Professor Dr. Joseph Schacht on how Ozempic may curb alcohol consumption.” <https://koacolorado.iheart.com/featured/colorado-s-morning-news/content/2023-09-06-cu-professor-dr-joseph-schacht-on-how-ozempic-may-curb-alcohol-consumption/>

Bloomberg News, October 18, 2023. “The Ozempic Effect Is Coming for Everything From Kidney to Heart Disease Treatments.” <https://www.bloomberg.com/news/features/2023-10-18/ghp-1-drug-benefits-like-ozempic-go-beyond-weight-loss>

Ivanhoe Broadcasting, December 3, 2023. “America’s Alcohol Crisis: Damaging our Bodies and Minds.” <https://www.ivanhoe.com/family-health/americas-alcohol-crisis-damaging-our-bodies-and-minds/>

Bloomberg News, December 5, 2023. "Can Wegovy Fight Alcoholism? For Big Pharma, This Isn't a Priority." <https://www.bloomberg.com/news/articles/2023-12-06/can-ozempic-wegovy-treat-alcoholism-for-big-pharma-it-s-not-a-priority>

2024

The Denver Post, January 4, 2024. "Colorado alcohol deaths surged 60% in 4 years, but there's been no public outcry or push to save lives." <https://www.denverpost.com/2024/01/04/colorado-alcohol-deaths-drinking-fentanyl-addiction/>

The Denver Post, January 4, 2024. "Am I drinking too much? Here are two ways to find out." <https://www.denverpost.com/2024/01/04/alcoholic-definition-drinking-abuse-disorder-colorado-treatments/>

CU Anschutz Newsroom, January 4, 2024. "Take the 'Dry January' Challenge. Here's How and Why". <https://news.cuanschutz.edu/news-stories/take-the-dry-january-challenge-heres-how-and-why>

The Washington Post, January 11, 2024. "FDA reports no link between weight-loss drugs and suicidal thoughts." <https://www.washingtonpost.com/health/2024/01/11/fda-ozempic-wegovy-suicide-safety/>

The Telegraph, January 14, 2024. "'On Ozempic I immediately lost all desire for alcohol'." <https://www.telegraph.co.uk/health-fitness/diet/weight-loss/ozempic-drinking-less/>

diaTribe Learn, January 22, 2024. "Beyond the Scale: Can Weight Loss Drugs Be the Next Frontier in Addiction Treatment?" <https://diatribe.org/beyond-scale-can-weight-loss-drugs-be-next-frontier-addiction-treatment>

Colorado Public Radio, January 23, 2024. Interviewed by John Daley for story on "Dry January."

KUSA 9NEWS, January 25, 2024. Interviewed by Anusha Roy for story on "Dry January." <https://www.youtube.com/watch?v=SfKKNdIPtS4>

KOA 850, January 31, 2024. "CU Professor Dr. Joseph Schacht on avoiding overindulging after dry January." <https://koacolorado.iheart.com/featured/colorado-s-morning-news/content/2024-01-31-cu-professor-dr-joseph-schacht-on-avoiding-overindulging-after-dry-january/>

KUNC, April 11, 2024. "Meet the mixologists shaking up Northern Colorado's nightlife with sober spaces." <https://www.kunc.org/news/2024-04-11/meet-the-mixologists-shaking-up-northern-colorados-nightlife-with-sober-spaces>

KMGH Denver7, December 5, 2024. "University of Colorado Anschutz Medical Campus studying if pill form of Ozempic can curb alcohol use". <https://www.denver7.com/news/front-range/aurora/university-of-colorado-anschutz-medical-campus-studying-if-pill-form-of-ozempic-can-curb-alcohol-use>

KOA 850, December 31, 2024. "CU Professor Dr Joseph Schacht on how to have a successful Dry January." <https://koacolorado.iheart.com/featured/colorado-s-morning-news/content/2024-12-31-cu-professor-dr-joseph-schacht-on-how-to-have-a-successful-dry-january/>

2025

KUSA 9NEWS, January 1, 2025. “Colorado researchers lead trial studying if weight-loss drugs can curb alcohol cravings.” <https://www.9news.com/article/news/local/colorado-researchers-studying-weight-loss-drugs-alcohol-cravings/73-8865655b-1fc8-419d-822e-34379add7ad1>

National Public Radio, January 2, 2025. “Cutting out alcohol for Dry January? These apps can help.” <https://www.npr.org/sections/shots-health-news/2025/01/03/nx-s1-5246601/dry-january-apps-drinking-less-alcohol>

The New York Times, January 24, 2025. “How to Rethink Your Drinking This Year.” <https://www.nytimes.com/2025/01/24/well/dry-january-maintenance.html>

CU Anschutz Newsroom, February 7, 2025. “CU Researcher Studying Effects of GLP-1 Drugs on Alcohol Addiction.” <https://news.cuanschutz.edu/medicine/cu-researcher-studying-effects-of-glp-1-drugs-on-alcohol-addiction>

NBC News, February 10, 2025. “New treatments are needed for alcohol addiction. Are drugs like Ozempic the answer?” <https://www.nbcnews.com/health/health-news/ozempic-alcohol-addiction-latest-science-shows-rcna191015>

The New York Times, February 12, 2025. “Ozempic Can Curb Drinking, New Research Shows.” <https://www.nytimes.com/2025/02/12/well/ozempic-alcohol-use.html>

Colorado Public Radio, February 14, 2025. “Aha Moments for Treating Alcohol Use Disorder”. Interviewed by Ryan Warner on “Colorado Matters”. <https://www.cpr.org/show-episode/feb-14-2025-aha-moments-for-treating-alcohol-use-disorder-sustained-empowers-indigenous-culture-art/>

Colorado Public Radio, February 22, 2025. “Weight-loss drugs could revolutionize treatment for alcohol addiction.” <https://www.cpr.org/2025/02/22/interview-weight-loss-drugs-could-treat-alcoholism/>

taz, March 3, 2025. “Medikament gegen Diabetes soll in der Suchtmedizin helfen”. [“Drugs against diabetes should help in addiction medicine”]. <https://taz.de/!a191349/>

Everyday Health, March 26, 2025. “Could Ozempic and Other GLP-1 Drugs Treat Alcohol Use Disorder?” <https://www.everydayhealth.com/addiction/could-ozempic-and-other-glp-1-drugs-treat-alcohol-use-disorder/>

CU Anschutz Newsroom, July 18, 2025. “Hot Temps, Cold Drinks: Staying Safe When Summer and Alcohol Collide.” <https://news.cuanschutz.edu/news-stories/hot-temps-cold-drinks-staying-safe-when-summer-and-alcohol-collide>

PsyPost, August 22, 2025. “Dopamine-boosting drug enhances self-control and reduces drinking in people with alcohol use disorder.” <https://www.psypost.org/dopamine-boosting-drug-enhances-self-control-and-reduces-drinking-in-people-with-alcohol-use-disorder/>

Health, August 29, 2025. “What Happens to Your Body When You Stop Drinking Alcohol.” <https://www.health.com/what-happens-body-stop-drinking-alcohol-11799458>

CU Anschutz Newsroom, September 30, 2025. “CU Anschutz School of Medicine Researchers Identify New Method for Treating Alcohol Use Disorder.”

<https://news.cuanschutz.edu/medicine/tolcapone-alcohol-use-disorder>

Correio Braziliense, October 12, 2025. “Pesquisadores buscam novos caminhos para combater o alcoolismo”. [“Researchers seek new ways to combat alcoholism”].

<https://www.correiobraziliense.com.br/ciencia-e-saude/2025/10/7265824-pesquisadores-buscam-novos-caminhos-para-combater-o-alcoolismo.html>

CU Anschutz Newsroom, November 4, 2025. “How the End of Daylight Saving Time Can Affect Addiction and Substance Use.” <https://news.cuanschutz.edu/news-stories/how-the-end-of-daylight-saving-time-can-affect-addiction-and-substance-use>

Nature, December 2, 2025. “Will blockbuster obesity drugs revolutionize addiction treatment?”

<https://www.nature.com/articles/d41586-025-03911-x>

Nature Medicine, December 8, 2025. “Is addiction the next frontier for GLP-1 receptor agonists?”

<https://www.nature.com/articles/d41591-025-00069-x>

2026

The New Yorker, February 9, 2026. “Can Ozempic cure addiction?”

<https://www.newyorker.com/magazine/2026/02/16/can-ozempic-cure-addiction>

The Addiction Psychologist, March 11, 2026. “Dr. Joseph Schacht - Can We Leverage GLP-1s for Substance Use Disorder?” <https://podcasts.apple.com/us/podcast/dr-joseph-schacht-can-we-leverage-glp-1s-for-substance/id1517074983?i=1000754662125>

<https://podcasts.apple.com/us/podcast/dr-joseph-schacht-can-we-leverage-glp-1s-for-substance/id1517074983?i=1000754662125>

Healthbeat, March 12, 2026. “How new weight-loss drugs may offer hope for curbing addiction.”

<https://www.healthbeat.org/2026/03/12/global-health-checkup-weight-loss-drugs-addiction/>

BioSpace, March 30, 2026. “Lilly, Baseline Investigate GLP-1s’ Potential in Substance Use as Interest Mounts.” <https://www.biospace.com/drug-development/lilly-baseline-investigate-glp-1s-potential-in-substance-use-as-interest-mounts>

Science Friday, April 9, 2026. “Can GLP-1 drugs treat addiction?”

<https://www.sciencefriday.com/segments/glp-1-drugs-for-addiction-alcohol-smoking/>

The Washington Post, April 14, 2026. “The surprising ways cannabis may affect the aging brain.”

<https://www.washingtonpost.com/wellness/2026/04/14/cannabis-brain-health/>

CU Anschutz Today, July 29, 2026. “Can Oral Semaglutide Reduce Alcohol Use? CU Anschutz Clinical Trial Shows Fewer Heavy Drinking Days.” <https://news.cuanschutz.edu/news-stories/can-oral-semaglutide-reduce-alcohol-use-cu-anschutz-clinical-trial-shows-fewer-heavy-drinking-days>

<https://news.cuanschutz.edu/news-stories/can-oral-semaglutide-reduce-alcohol-use-cu-anschutz-clinical-trial-shows-fewer-heavy-drinking-days>

UCHealth Today, July 29, 2026. “GLP-1 weight-loss drugs may cut drinking and alcohol cravings, new study finds.” <https://www.uchealth.org/today/glp-1-weight-loss-drugs-may-reduced-alcohol-use-cravings/>

<https://www.uchealth.org/today/glp-1-weight-loss-drugs-may-reduced-alcohol-use-cravings/>

Newsweek, July 29, 2026. “An Ozempic Pill Was Tested on Heavy Drinkers—the Results Were Promising.” <https://www.newsweek.com/an-ozempic-pill-was-tested-on-heavy-drinkers-the-results-were-promising-12258770>

Forbes, July 29, 2026. The Drug Behind Ozempic And Wegovy Pills May Also Treat Alcohol Use Disorder, New Trial Finds.” <https://www.forbes.com/sites/antoniopequenoiv/2026/07/29/the-drug-behind-ozempic-and-wegovy-pills-may-also-treat-alcohol-use-disorder-new-trial-finds/>

Gizmodo, July 30, 2026. “A Daily GLP-1 Pill Could Curb Heavy Drinking.” <https://gizmodo.com/a-daily-glp-1-pill-could-curb-heavy-drinking-2000792946>

Inc., August 1, 2026. “This Breakthrough Weight-Loss Drug Reduced Heavy Drinking. Scientists Think They Know Why.” <https://www.inc.com/lucia-auerbach/breakthrough-weight-loss-drug-reduced-heavy-drinking-scientists-think-they-know-why/91382105>

Earth.com, August 1, 2026. “Weight-loss medication helps people drink less alcohol.” <https://www.earth.com/news/weight-loss-medication-helps-people-drink-less-alcohol/>

Minnesota Star Tribune, August 4, 2026. “Could GLP-1s curb problem drinking? Minneapolis VA is finding out.” <https://www.startribune.com/glp-1-alcohol-use-study-va-veterans-why/601874040>

KUSA 9NEWS, August 9, 2026. “CU Anschutz clinical trial finds GLP-1s help curb alcohol use disorder.” <https://www.9news.com/article/news/health/cu-anschutz-clinical-trial-glp-1s-alcohol-use-disorder/73-00b1a234-1d7d-4d58-bd77-b8c627211fc3>